Pierre Fabre Medicament

Samuel Mialhe

Elisabeth Dupont-Passelaigue

Didier Junquero

Karine Valeille

Jean-Pierre Rieu

Isabelle Le Roy

Christophe Pignier

Isabelle Leroy

Elisabeth Dupont-passelaigue

The present invention relates to diarylpyridazinone derivatives that block the potassium Kv channels (specifically the Kv1.5, Kv4.3, and Kv11.1 channels) and to the use thereof for the treatment of humans. Said compounds have the general formula (I), where Rand Rare simultaneously or independently one or more groupings such as: halogen, such as F, Br, Cl, a straight or branched C-Calkyl, hydroxy, a straight or branched C-Calkoxy, arylsulfonamido, in which the aryl is optionally replaced with a straight or branched C-Calkyl, or nitrile, as well as the various enantiomers and the mixtures thereof in any proportion, and the pharmaceutically acceptable salts thereof.

Diarylpyridazinone derivatives, preparation thereof, and use thereof for the treatment of humans

The present invention relates to compounds having general formula I characterized in that  

Nitrogen heterocycle derivatives, preparation thereof and application thereof in human therapeutics

The present invention concerns compounds of general formula (I) characterized in that (formula 1) wherein, in particular: &#x2014;Rrepresents one or more groups such as: trifluoromethyl, halogen such as F, Cl, &#x2014;when n=m=1, W represents CH then Y represents oxygen, &#x2014;U represents: &#x2022;either &#x2014;(C&#x2550;O)CHNH&#x2014; and is branched at position 4 of pyridazinone, then R2 represents H, &#x2022;or &#x2014;(C&#x2550;O)NH&#x2014; and U is branched at positions (4), (5) or (6) of pyridazinone, then R2 represents H, &#x2014;R3 represents a hydrogen or methyl and the addition salts with pharmaceutically acceptable bases and acids and the different isomers, and their mixtures in any proportion for use as SCD-1 enzyme inhibitors for the treatment of obesity, type-2 diabetes and lipid disorders. 

Derivatives of 2H pyridazin-3-ones, their preparation and their use as SCD-1 inhibitors

Growing community of inventors

Castres, France

Samuel Mialhe